The current study characterizes the mitosis-associated histone dual modification on the core of histone H3: trimethylation of histone H3 lysine 79 and simultaneous phosphorylation of H3 threonine 80 (H3K79me3T80ph). Through the use of protein and microscopy-based techniques, we find that H3K79me3T80ph shares a similar spatial and temporal regulation as H3S10ph but additionally requires methyltransferase activity. In addition, we find that Aurora kinase activity is necessary for the catalysis of H3K79me3T80ph in vivo. Finally, our analysis of H3K79me3T80ph using a tissue microarray indicates that H3K79me3T80ph marks a subset of primary cutaneous melanomas with metastatic potential indicating that H3K79me3T80ph may identify a subset of invasive melanomas with a more aggressive clinical behaviour.
Introduction
The nucleosome is the fundamental unit of chromatin; it consists of an octamer of core histones proteins (2 molecules each of H3, H4, H2A, and H2B) around which DNA is wrapped. Core histones are characterized by an unstructured N-terminal tail and the histone fold motif. Lysine residues on histone H3 can be mono-, di-, or trimethylated (me1, me2, and me3 resp.), with the majority of H3 methylation marks residing on the N-terminal tail of H3 [1] . However, lysine methylation can also occur on an exposed region of the histone H3 core at lysine 79 (H3K79) [2] . H3K79 methylation is catalyzed by DOT1, which has been implicated in cell-cycle regulation in both yeast and mammals [2] [3] [4] [5] . On the tail of H3, three methylatable lysines lie adjacent to residues that have been found to be phosphorylated during mitosis, T3/K4, K9/S10, and K27/S28 [6] [7] [8] . However, it is not clear in what capacity lysine methylation and the adjacent phosphorylations occur together during mitosis or what the role is of these methyl-phospho modifications.
On the core of histone H3, methylatable K79 lies adjacent to threonine 80, which was found, in a massspectrometry screen, to be phosphorylated (H3T80ph) in an analysis of adult mouse brain [9] . To our knowledge no reports have directly reported H3T80 phosphorylation (with or without the neighbouring K79 methylation), making this the first examination of a histone dual modification consisting of H3K79 trimethylation and H3T80 phosphorylation (H3K79me3T80ph) in the chromatin environment. Using a monoclonal antibody putatively recognizing H3K79me3T80ph, we find that H3K79me3T80ph is primarily associated with mitotic chromosomes. However unlike H3S10ph, H3T80ph does not appear to be catalyzed by Aurora B. Finally, using a tissue microarray we find that H3K79me3T80ph labels a subset of primary cutaneous melanomas with metastatic potential.
Materials and Methods

Cell Culture.
Culturing of UCD-Mel-N and IIB-Mel-N cells has been previously described [10] . HeLa cells were grown in DMEM supplemented with 10% fetal bovine serum. For cell synchronization experiments, cells were treated with 0.1 μg/mL of colcemid (Roche) for 16 hours and with 10 μM of MG132 for the last 3 hours of treatment. Mitotic cells were then isolated by mitotic shake off. ZM 447439 (Enzo Life Sciences) was used at 0.5, 1, and 2 μM. When ZM447439 was used in conjunction with colcemid, treatments were added simultaneously and incubated for 16 hours.
Histone Purification.
Histones were isolated by acid extraction as previously described [11] . 
Peptides.
Biotinylated peptides having sequence homology to histone H3 amino acids 71-88 were generated, and the peptide sequence is as follows: Biotin-Val-Arg-GluIle-Ala-Gln-Asp-Phe-Lys-Thr-Asp-Leu-Arg-Phe-Gln-SerSer/Ala-Ala-OH. Unmodified, K79T80ph, K79me2T80, and K79me2T80ph peptides were generated by Genemed Synthesis. K79me1T80, K79me3T80, and K79me3T80ph were generated by Keck Biotechnology Resource Laboratory, Yale University. H3 (1-21) and biotinylated H3 (1-21) phospho-(S10) are commercially available (Anaspec).
Western Blotting.
Western blotting was performed as previously described [12] .
Immunofluorescence.
Immunofluorescence was performed as previously described [12] . Fluorescent images were obtained using an Axio Imager M1 microscope and AxioCam MRm camera utilizing AxioVision Rel. 4.6.3 software (Carl Zeiss, Inc.).
Peptide
Competition. 25 μg of acid-extracted histones were fractionated by SDS-PAGE and transferred to nitrocellulose membrane (Bio-Rad). 15 μM of each peptide was preincubated with H3K79me3T80ph antibody for 1 hour. Membranes were then incubated with antibody/ peptide mixture for 1 hour, and western blotting was completed using standard protocol.
Peptide Dot Blot.
Increasing amounts of peptides (50, 100, 150, 200, and 250 nmoles) were transferred to PVDF membrane (GE Healthcare Life Sciences) by the use of dot blot apparatus. H3K79me3T80ph western blotting was completed using standard method. To demonstrate equal peptide spotting, the membranes were incubated with Avidin-HRP, extensively washed, and detected using an ECL detection kit (Denville Scientific).
Flow Cytometry. 1×10
6 HeLa cells were isolated for each flow cytometry reaction. Cells were fixed in 1% formaldehyde and washed with PBS, and stored in 70% ethanol at −20 • C for 24 hours. Fixed cells were permeabilized with 0.1% Triton-X-100 in PBS and blocked with 3% BSA in PBS. Primary antibody was incubated for 1 hour in 1% BSA, followed by a 30-minute incubation with Alexa Fluor-488 secondary antibodies (Invitrogen) in 1% BSA. For propidium iodide staining cells were incubated for 10 minutes with 0.1 mg/mL RNase A then stained with 10 μg/mL of propidium iodide. All reactions were suspended in 1 mL of water prior to analysis.
Cells were analyzed at the Cytometry and Cell Sorting Core (Baylor College of Medicine), using a LSRFortessa (BD Biosciences). Data from 20,000 events were analyzed using FloJo software (Tree Star Inc.). Data bars represent the mean (± S.E.M), n = 3. Statistical analysis was performed using a Student's t-test; results were considered significant if P < 0.05.
2.10.
In Vitro Kinase Assays. 6 ng of Aurora B/INCENP (Millipore) was added to reaction buffer (20 mM Tris, pH 7.5, 1 mM EGTA, 10 mM MgCl, 1 mM NaF, 0.1 mM Na 3 VO 4 , 1 mM DTT, and 50 μM ATP) with 30 μM of peptide and 5 μCi of γ-32 P-ATP (specific activity 2,500 Ci/mmol; Perkin Elmer) and was then incubated at 30
• C for 30 min. Reactions were stopped by the addition of 3% phosphoric acid, and the products were captured on P81 nitrocellulose filters (Millipore). P81 filters were washed in 0.75% phosphoric acid and methanol and subsequently assayed for incorporation of 32 P by scintillation counting. Val-Arg-Glu-Ile -Ala-Gln-Asp-Phe-Lys-Thr-Asp-Leu-Arg-Phe-Gln-Ser-(Ser/Ala) -Ala a dermatopathologist. Tissue array construction was performed as previously described [13] .
2.12.
Immunohistochemistry. Immunohistochemical studies were performed as previously described [12] . H3K79me3T80ph antibody was used at a 1 : 100 dilution.
Statistical Analysis of Melanoma Tissue
Array. The number of anti-H3K79me3T80ph positive cells (mitotically active cells and cells with speckled nuclear pattern) per highpower field in the melanoma tissue array was scored by two dermatopathologists (J. L. Curry, C. Torres-Cabala). The intensity of labelling was scored as no labelling, weak, moderate, and strong. Associations between average number of H3K79me3T80ph positive cells and categorical variables were examined using the analysis of variance (JMP software, Cary). Results were considered significant if P < 0.05. Significance levels were not adjusted for multiple comparisons.
Results and Discussion
H3K79me3T80ph Antibody Specifically Recognizes Both Trimethylated Lysine and Phosphorylated Threonine.
Although the dual modification H3K79meT80ph has been suggested, and the antibody for this modification is commercially available, to our knowledge no studies have been reported for this modification [14] . Therefore, we initiated experiments aimed at determining the specificity of this antibody. To do so, biotinylated peptides representing 18 amino acids of H3 (residues 71-88) and containing various levels of lysine methylation at lysine 79 (H3K79) in the presence and absence of phosphorylation at threonine 80 (H3T80) were generated (Figure 1(a) ). A peptide competition assay was performed in which the H3K79me3T80ph antibody was either untreated (no peptide) or preincubated with H3 peptides containing modifications at K79me3T80ph, T80ph, or S10ph. The antibody/peptide mixture was then used to perform a western blot on extracted histones. Complete loss in signal was observed with the peptide containing both K79me3 and an adjacent T80ph showing that the antibody is highly specific for the dual H3K79me3T80ph modification (Figure 1(b) ). An H3T80ph peptide successfully competed for antibody binding, indicating that the antibody may also recognize H3T80ph alone (Figure 1(b) ). Having seen that the presence of H3T80ph alone can prevent antibody recognition of histones, we next examined the extent to which the H3K79me3T80ph antibody reacts with peptides containing different levels of K79 methylation adjacent to phosphorylated T80. Increasing molar amounts of peptides containing T80ph alone, and in combination with mono-, di-, or trimethylated K79 (K79me1T80ph, K79me2T80ph, and K79me3T80ph resp.), were spotted onto nitrocellulose and subjected to H3K79me3T80ph western blotting. The H3K79me3T80ph antibody had strongest immunoreactivity with the K79me3T80ph peptide (Figure 1(c) ). In addition, the H3K79me3T80ph antibody reacts much more strongly with the K79me3T80ph peptide than the T80ph peptide, suggesting that the competition seen with the T80ph peptide in the peptide competition may be the result of decreased sensitivity in the immunoblot assay. To ensure that the H3K79me3T80ph antibody does not recognize lysine methylation in the absence of adjacent T80 phosphorylation, the dot blot analysis was repeated comparing a K79me3T80ph peptide to those containing methylated K79 alone (Figure 1(d) ). Once again, the H3K79me3T80ph antibody shows a very specific immunoreactivity with the K79me3T80ph peptide and no reactivity against peptides containing only methylated K79.
H3K79me3T80ph Occurs Primarily in Proliferating Cells.
We next compared H3K79 methylation to H3K79me3T80ph patterns in various human melanoma cell lines and in nondividing senescent melanocytes. Western blot analysis of H3K79me2 and H3K79me3 identified cell-line specific patterns of H3K79 methylation (Figure 2(a) ). This analysis also revealed that H3K79me3 and H3K79me3T80ph do not share a similar pattern of occurrence, indicating that these modifications are differentially regulated (Figure 2(a) ). A similar pattern was observed in normal human melanocytes (NHMs), where H3K79me3 was found to be present in both proliferating and senescent NHMs, whereas H3K79me3T80ph was only detectable in proliferating NHMs (Figure 2(b) ). Together this data suggest that H3K79me3T80ph is associated with cell proliferation; however, H3K79me3T80ph was undetectable in A375, SK Mel 93.3, SK Mel 110, and UCD-Mel-N melanoma cell lines paired with H3T80ph [15, 16] .
H3K79me3T80ph is Cell Cycle Regulated. Given that
H3K79me3T80ph is detectable only in proliferating cells, we sought to determine whether H3K79me3T80ph is cell-cycle regulated. HeLa and the human melanoma cell lines UCDMel-N and IIB-Mel-N were synchronized in mitosis with colcemid or vehicle treated [17, 18] . Synchronization was confirmed by Cyclin B1 western blot of whole cell extract (Figure 2(c) ). H3K79me3T80ph levels were undetectable by western blot in asynchronous populations but increased significantly upon mitotic synchronization with colcemid, indicating that H3K79me3T80ph is indeed regulated in a cell-cycle-dependent manner (Figure 2(c) ).
The dynamics of H3K79me3T80ph during the cell cycle were analyzed by flow cytometry. HeLa cells were indirectly stained for H3K79me3T80ph, and propidium iodide was used to determine DNA content. The cell-cycle phases were gated based on their DNA content, and the percentage of H3K79me3T80ph-positive cells was determined. Flow cytometry analysis revealed that G 0 /G 1 and S phases have essentially undetectable levels of H3K79me3T80ph-positive cells (0.03% and 0.06%, resp.), whereas the number of H3K79me3T80ph-positive cells increased significantly in G 2 /M to 7.6% (p G0/G1−G2/M = 0.0014, p S−G2/M = 0.0016; Figures 3(a), and 3(b) ). To verify that mitotic synchronization with colcemid increases the number of H3K79me3T80ph-positive cells, flow cytometry was repeated comparing the H3K79me3T80ph histogram in asynchronous and colcemid treated populations. The proportion of H3K79me3T80ph-positive cells in the population increased upon mitotic synchronization with colcemid, causing a positive shift in the H3K79me3T80ph histogram (data not shown).
H3K79me3T80ph is Primarily Associated with Mitotic Chromosomes. Having established that H3K79me3T80ph is G 2 /M associated, we next examined its localization in vitro.
Immunofluorescence of H3K79me3T80ph in UCD-Mel-N cells demonstrates that H3K79me3T80ph is primarily associated with chromatin throughout mitosis (Figure 3(c) ). Punctate H3K79me3T80ph staining was also observed in G 2 cells with uncondensed DNA (Figure 3(c) , first panel).
H3S10ph is a well-studied mitotic histone modification that appears to share the similar dynamic as H3K79me3T80ph persisting on chromosomes until anaphase [7] . To gain insight into the regulation of H3K79me3T80ph, we compared the spatial-temporal regulation of H3K79me3T80ph to that of H3S10ph. Coimmunofluorescence in UCD-Mel-N cells demonstrated that H3K79me3T80ph and H3S10ph colocalize completely throughout mitosis (Figure 3(d) ). This colocalization also occurs prior to chromosome condensation, suggesting that, like H3S10ph, H3K79me3T80ph appears in late G 2 [7] .
Aurora B is Necessary for Catalysis of H3K79me3T80ph.
Aurora B is a well-described mitotic kinase that catalyzes N-terminal H3 mitotic phosphorylation at H3S10ph and H3S28ph [7] . Having seen that H3K79me3T80ph appears to share the same pattern of regulation as H3S10ph, we examined if Aurora B is involved in H3K79me3T80ph regulation by culturing HeLa cells in the presence of colcemid and ZM447439, a potent Aurora B inhibitor [19] . Colcemid treatment alone resulted in a robust H3K79me3T80ph signal; however, this detection was loss in the presence of ZM447439 (Figure 4(a) ). It has been reported previously that although ZM447439 inhibits Aurora B, treated cells can still exit mitosis with normal dynamics [19] . Cyclin B1 western blot of whole cell extract from cells treated with colcemid and ZM447439 treatment verifies that the cells were arrested in mitosis; therefore, loss of H3K79me3T80ph is not due to mitotic exit (Figure 4(a) ).
To directly address whether Aurora B can phosphorylate H3T80, an in vitro kinase assay was performed using recombinant human Aurora B and INCENP, a protein important for stimulating Aurora B kinase activity [20] . Aurora B/INCENP was incubated with biotinylated H3 peptides (H3 (71-88), H3 (71-88) K79me3, and H3 (1-21)) in the presence of 32 P-ATP. The level of 32 P incorporation was determined by scintillation counting, which was compared to peptides incubated with cold phosphate (H3 (71-88) T80ph, H3 (71-88) K79me3T80ph, and H3 (1-21) S10ph. Recombinant Aurora B/INCENP robustly phosphorylated the H3 (1-21) peptide, presumably on S10, but was unable to phosphorylate the H3 (71-88) peptide to the same extent, whether the peptide was unmodified or trimethylated (Figure 4(b) ). Together these results indicate that Aurora B/INCENP is necessary for T80 phosphorylation in vivo, but not sufficient for H3T80 phosphorylation in an in vitro peptide kinase assay. Aurora B is a member of several protein complexes and may require additional proteins to target its activity toward H3T80 in vivo. However, the H3 (71-88) peptide used here derives from the core domain of H3 and, in vitro, may not possess the structure or sufficient residues for proper T80 phosphorylation, unlike the H3 (1-21) peptide which likely exists in an unordered state in vitro as the H3 tail does in vivo making it suitable for Aurora B activity.
Previous reports have demonstrated that phosphorylation of H3T3 by Haspin greatly increases Aurora B activity toward H3S10 and H3S28. Similar to H3T80, H3T3 lies adjacent to a well-described methylation mark at H3K4; therefore, we wanted to determine if Haspin was capable of phosphorylating H3T80. In vitro kinase assays using recombinant Haspin and biotinylated H3 (1-21) and H3 (71-88) were performed in the presence of 32 P-ATP. Consistent with published reports, Haspin was capable of phosphorylating the H3 (1-21) peptide. However, Haspin was unable to phosphorylate the H3 (71-88) peptide, demonstrating that Haspin, like Aurora B, is not sufficient for the phosphorylation of H3T80 (data not shown).
H3K79me3T80ph is an Indicator of Tumor Proliferation and Mitosis In Vivo.
We next sought to determine if H3K79me3T80ph staining was capable of detecting proliferation differences in human melanoma samples using a tissue microarray. The array included 87 lesions consisting of benign melanocytic nevi, primary cutaneous melanomas with and without known metastasis, and metastatic melanomas. The array was stained for H3K79me3T80ph, and positive cells per high-power field were counted. H3K79me3T80ph was primarily observed in a speckled nuclear pattern and on chromosomes of mitotically active cells within the melanoma sections but was not detectable in melanocytic nevi (Figures 5(a), 5(b), and 5(c) ). Further analysis demonstrated that the average number of H3K79me3T80ph-positive cells per high-powered field was significantly higher in all subcategories of melanomas when compared to benign melanocytic nevi ( Figure 5 
Conclusion
The interplay between histone modifications is the foundation of the histone code hypothesis [21] . Through the use of cell synchronization experiments, flow cytometry, and immunofluorescence studies, we have found that H3K79me3T80ph is a novel histone dual modification in the core of histone H3. H3K79me3T80ph becomes visible prior to the onset of obvious chromosome condensation. Therefore, it is likely that the dual modification appears in G 2 . This is further supported by our immunofluorescence studies showing that H3K79me3T80p shares the same temporal regulation as H3S10ph, which is known to appear in late G 2 [7] . However, our investigation into the regulation of H3K79me3T80ph revealed that, unlike the N terminus of histone H3, Aurora B is not sufficient to catalyze H3T80ph in vitro although Aurora kinase activity is required for the catalysis of H3K79me3T80ph. Considering that there are many mitotic kinases, H3T80 phosphorylation may be catalyzed by an unidentified kinase that may require Aurora B for its own activation, which would explain why the inhibition of Aurora kinase activity via ZM447439 treatment results in loss of H3K79me3T80ph. However, it is also reasonable to speculate that Aurora B in vivo can phosphorylate H3T80 but requires additional proteins to target Aurora B kinase activity toward H3T80. A similar instance has been observed for H3S10ph and survivin. Survivin is a member of the chromosome passenger complex with Aurora B and INCEP, and upon phosphorylation of H3T3 survivin directs Aurora B activity toward H3S10ph [22, 23] . However, even in the absence of survivin Aurora B shows activity toward H3S10, which is not the case for H3T80. Furthermore, the sequence surrounding H3K79/T80 and F78-K79-T80, does not match the Aurora B consensus sequence (R/K-X-S/T), meaning that Aurora B is not predicted to be a T80 kinase but likely lies upstream of the H3T80 kinase [24] . In addition, H3K79me3T80ph appears to identify a subset of primary cutaneous melanomas with metastatic potential. Melanoma is the deadliest of all skin cancers, and proper diagnosis and risk stratification are important for treatment and prognosis. Mitotic rate in primary cutaneous melanoma has been determined to be the second most powerful predictor of survival, immediately after tumor (Breslow) thickness [25] . Ancillary IHC studies with H3S10ph (PHH3) have been shown to be an additional clinical tool to evaluate for mitoses in melanoma [26] . The value of histone H3 N-terminal modifications as a prognostic marker of invasive melanoma in a clinical setting is emerging; however, the utility of specific proliferative markers as prognostic indicator appears context dependent. For instance, a study by Ladstein et al. examined H3S10ph (PHH3) in nodular invasive melanomas and found that although H3S10ph is a mitotic marker, it did not demonstrate prognostic value for nodular melanomas [27] . We have detected H3K79me3T80ph in primary cutaneous melanomas, and it appears to identify a subset of primary melanomas with metastatic potential. Additional studies on separate cohorts may be needed to determine possible clinical applications, but our results reveal a possible use of H3K79me3T80ph as a biomarker for the identification of primary cutaneous melanoma with more aggressive clinical behaviour.
